59 results on '"Shrimanker, R"'
Search Results
2. Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
3. P106 Multidisciplinary assessment of inducible laryngeal obstruction (ILO) & upper airway symptoms in severe Asthma. Single centre experience of service development & outcomes
4. A novel ct scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma: P227
5. Seasonality of eosinophilic and non-eosinophilic exacerbations of copd: P187
6. Management and mechanisms of severe eosinophilic asthma
7. FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
8. S92 FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
9. P99 The value of oral prednisolone in patients with severe eosinophilic asthma on mepolizumab treatment
10. S128 CyTOF and in vitro analysis of the role of IL-17A in asthma
11. P13 Exhaled nitric oxide and blood eosinophil count in predicting sputum inflammatory type in a heterogeneous airways disease population
12. S136 Relationship between inflammatory type of obstructive airways disease and lung function in a cohort of the oxford special airways clinic
13. S51 Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo
14. Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
15. Effects of steroids in cultured human type-2 cytokine producing cells
16. The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
17. A novel CT scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma
18. Characterisation of Exacerbations of Severe Eosinophilic Asthma on Mepolizumab Compared to Placebo
19. Fractional Exhaled Nitric Oxide and Peripheral Blood Eosinophil Count Prognostic and Predictive Biomarkers in Severe Eosinophilic Asthma
20. P46 Treatable traits in a severe asthma cohort
21. S83 Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
22. P135 Recognition of eosinophilic asthma: are routine clinical measures useful?
23. Peripheral blood eosinophil drop-to-drop variation in patients with COPD using near patient testing: a small validation study
24. Sputum Il-17a levels correlate with biomarkers of non-eosinophilic inflammation in patients with asthma
25. Interaction of type 2 cytotoxic T lymphocytes and mast cell lipid mediators contributes to pathogenesis of eosinophilic asthma
26. Inhibition of asthma relevant innate and adaptive human immune cells by epithelial cells
27. P227 A novel ct scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma
28. P187 Seasonality of eosinophilic and non-eosinophilic exacerbations of copd
29. Non-invasive ventilation: initiation and initial management
30. P234 Sputum cytokines and clinical biomarkers in severe asthma
31. Pre-existing oral contrast from lanthanum carbonate: a confounding factor in CT mesenteric angiography
32. P187 Seasonality of eosinophilic and non-eosinophilic exacerbations of copd
33. P227 A novel ct scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma
34. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
35. Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo.
36. Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE).
37. Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation.
38. Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.
39. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
40. Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma.
41. Current red cell transfusion practice: are we too liberal with this precious resource?
42. Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.
43. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis.
44. Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.
45. Letting the right one in: evaluating the generalisability of clinical trials.
46. Exacerbations of severe asthma in patients treated with mepolizumab.
47. Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.
48. Will precision medicine become an effective tool for airway disease?
49. A new approach to the classification and management of airways diseases: identification of treatable traits.
50. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.